FDA’s 2026 Good AI Practice principles emphasize context of use, multidisciplinary expertise, data governance, lifecycle management, and clear essential information. That means the regulator is signaling that successful AI use in life sciences depends not only on technical capability, but on controlled deployment and oversight.
For PV professionals, that creates a career opening. People who understand safety operations, documentation, review logic, and compliance may be well placed to help organisations deploy AI responsibly, even if they are not building the models themselves. This is an inference, but it follows directly from the governance-heavy nature of FDA’s framework.
In 2026, AI skill alone may not be the differentiator. AI governance literacy may be.
0 Comments